R&D News | pharmaphorum

News

Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.

News

A new digital platform designed to make it easier for GPs in the NHS to participate in clinical trials has been formally launched in the UK.

News

A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.

News

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

Kelonia only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but will report impressive results at ASH next month.

News

Novo Nordisk has decided to move its amycretin into pivotal trials in type 2 diabetes after a phase 2 readout.